Compare EARN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | CNTB |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 140.4M |
| IPO Year | 2012 | 2020 |
| Metric | EARN | CNTB |
|---|---|---|
| Price | $4.24 | $1.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.38 | ★ $8.67 |
| AVG Volume (30 Days) | 269.8K | ★ 1.8M |
| Earning Date | 06-16-2026 | 08-13-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.10 | $0.99 |
| 52 Week High | $5.72 | $3.82 |
| Indicator | EARN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 28.55 |
| Support Level | N/A | N/A |
| Resistance Level | $4.49 | $2.78 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 72.31 | 0.00 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.